CGEN News and Press, Compugen Ltd. From 08/08/25

2025-08-08 05:13:50 ET Compugen ( CGEN ) is gearing up for several catalysts over the next few years. Its key program is the development of its potential best-in-class anti-PVRIG antibody COM701 which is being explored in the ongoing phase 1/2 MAIA-ovarian study targ...

2025-08-07 06:30:57 ET More on Compugen Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on Compugen Historical earnings data for Compugen Financial informa...

2025-08-07 06:30:31 ET Compugen Ltd. (CGEN) Q2 2025 Earnings Conference Call August 06, 2025, 08:30 AM ET Company Participants Anat Cohen-Dayag - CEO, President & Director David Silberman - Chief Financial Officer Eran Ophir - Chief Scientific Officer Mic...

2025-08-06 07:02:00 ET More on Compugen Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on Compugen Historical earnings data for Compugen Financial information for Compugen Read the full article on Seeking A...

Sera Prognostics Inc. (SERA) is expected to report $-0.21 for Q2 2025 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.51 for Q2 2025 Context Therapeutics Inc. (CNTX) is expected to report $-0.06 for Q2 2025 Genco Shipping & Trading ...

Compugen Reports Second Quarter 2025 Results PR Newswire First patient dosed in MAIA-ovarian platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in July 2025 Pooled analysis from three previously reported Phase 1 trials ...

Compugen Ltd. (CGEN) is expected to report $-0.06 for Q2 2025

2025-08-05 18:00:57 ET Major earnings expected before the bell on Wednesday include: The Walt Disney Company ( DIS ) Shopify ( SHOP ) McDonald's Corporation ( MCD ) Aurora Cannabis ( ACB ) Uber Technologies ( UBER ) Read the full article on ...

2025-08-05 10:48:16 ET More on Compugen Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on Compugen Historical earnings data for Compugen Financial information for Compugen Read the full article on Seeking A...

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025 PR Newswire HOLON, Israel , July 28, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company ...